Mount Sinai Newsletter - COVID-19 Research










Mount Sinai First in U.S. to Use Artificial Intelligence to Analyze COVID-19 Patients


Mount Sinai researchers are the first in the country to use artificial intelligence (AI) combined with imaging, and clinical data to analyze patients with COVID-19. They have developed a unique algorithm that can rapidly detect COVID-19 based on how lung disease looks in computed tomography (CT scans) of the chest, in combination with patient information including symptoms, age, bloodwork, and possible contact with someone infected with the virus. This study, published in Nature Medicine, could help hospitals across the world quickly detect the virus, isolate patients, and prevent it from spreading during this pandemic. Click here for more information



Clinical Trial for COVID-19 Immune Therapy starts at Mount Sinai


Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients. Click here for more information



Mount Sinai Researchers Develop Potential Quantitative Serologic Test for COVID-19; Seek Emergency Authorization from FDA

Mount Sinai Health System has submitted a request to the U.S. Food and Drug Administration (FDA) for issuance of an Emergency Use Authorization (EUA) for quantitative use of its serologic test. If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma. Click here for more information



Mount Sinai Researchers: Low-Carbohydrate Diet May Be Associated With Lower Risk of Glaucoma

Following a long-term diet that’s low in carbohydrates and high in fat and protein from vegetables may lower the risk of the most common subtype of glaucoma. In a first-of-its-kind study, a researcher at New York Eye and Ear Infirmary of Mount Sinai (NYEE) helped discover that if at-risk groups adhere to these dietary restrictions, they may reduce their risk of developing primary open angle glaucoma with early paracentral visual loss by 20 percent. Results from the research have been published in        the Eye-Nature journal. Click here for more information



Mount Sinai Researchers Discover A Topical  Treatment Which Improves Chronic Plaque Psoriasis

Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. Click here for more information


         Hospital Development & Advisory Services›
         Clinical Service Line Development & Advisory Services›
         Education and Training›



         In the News
         Continuing Medical Education›
         Clinical Trials
         Inside Mount Sinai Blog
         Health Information Library & Resources


                            Mount  Sinai Health System | Find a Doctor | Request an Appointment | Our Locations | Patient Care | About Us                            

Back to Member News